

I hereby certify that this correspondence is being transmitted via the Office electronic filing system to the U.S. Patent and Trademark Office on the date shown below.

Dated: April 6, 2009

Signature: /Mark D. Russett/
Mark D. Russett, Reg. No.: 41,281

Docket No.: 59752(70207)
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
David Butler et al.

Application No.: 10/575,177

Confirmation No.: 7290

Filed: September 11, 2007

Art Unit: 1626

For: PYROVALERONE ANALOGUES AND
THERAPEUTIC USES THEREOF

Examiner: K. Bianchi

RESPONSE TO RESTRICTION REQUIREMENT

MS Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir/Madam:

This is a response to the Restriction Requirement mailed on February 3, 2009 (the "Restriction Requirement" or "Office Action"), in the above-referenced patent application. As the response was initially due on March 5, 2009, and a request for an extension of time through and including April 6, 2009, is being filed herewith (April 5, 2009, being a Sunday), it is believed that this response is timely filed.

Applicant respectfully traverses the Restriction Requirement and requests reconsideration on the grounds that consideration and examination of the groups specified in the Restriction Requirement should not impose an undue burden. Additionally, significant expense and time would be saved if all pending claims were searched and examined at this time.

However, to ensure a complete response, Applicant elects the species of claim 1 in which the compound has the structure: